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Capecitabine and gemcitabine are used in the treatment of
a variety of solid tumors including pancreatic and biliary tract
carcinomas. The authors evaluated survival, response, and toxi-
city associated with using a combination of capecitabine and
gemcitabine to treat patients with unresectable or metastatic
gallbladder adenocarcinoma (GBC). Eligible patients had histo-
logically- or cytologically-confirmed GBC, no prior systemic
therapy with capecitabine or gemcitabine, Karnofsky Perfor-
mance Status 70%, serum total bilirubin up to three times nor-
mal, and measurable disease. Treatment consisted of gemcita-
bine 1000 mg/m
2 IV on Days 1 and 8 concurrent with admini-
stration of capecitabine 1000 mg/m
2 PO BID on Days 1
through 14, on a 3-week cycle. Tumor response was assessed
by the response evaluation criteria in solid tumors (RECIST
criteria) and survival was calculated from initiation of CapGem
therapy. A total of 24 patients were enrolled. Median age at
the time of diagnosis was 62 years (range, 41-78 years). Four-
teen patients had undergone prior surgery. Results showed that
eight patients achieved partial response (33%) with an additio-
nal 10 patients achieving stable disease (42%). The overall
median time to disease progression was 6.0 months (95% CI,
3.8-8.1 months) and overall survival was 16 months (95% CI,
13.8-18.3 months). The one-year survival rate was 58%. No
Grade 4 toxicity was seen. Transient Grade 3 neutropenia/
thrombocytopenia and manageable nausea, hand-foot syndrome
and anorexia were the most common toxicities. Our study
shows that CapGem is an active and well-tolerated chemo-
therapy regimen in patients with advanced GBC.
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INTRODUCTION
Most patients with GBC present with invasive,
inoperable disease. Chemotherapeutic agents in-
cluding 5-fluorouracil (5-FU), mitomycin C, cispla-
tin, methotrexate, etoposide, and doxorubicin
have been tried alone, and in combination, for this
patient group. Partial responses lasting from
weeks to several months have been observed only
in about 10-20% of the cases, and the median
survival for patients with gallbladder cancer is
dismal at around four months.
1 Chemo-immuno-
therapy has shown encouraging results,
2,3 but the
data are limited to a few case reports only. Simi-
larly, isolated reports of intra-arterial chemother-
apy
4 and intra-lesional therapy
5 have been pub-
lished. The poor therapeutic results, along with
small sample sizes in the trials, preclude the sup-
port of any particular chemotherapeutic regimen
for unresectable disease. Therefore, newer, more
effective treatment strategies must be evaluated.
Several reports have suggested that gemcitabine
(Gemzar ; Eli Lilly, Indianapolis, IN, USA) may
act on biliary tract tumors and GBC.
6,7 A sub-
sequent Phase II studies using a weekly dose of
1000 mg/m
2 of gemcitabine for three out of four
weeks showed a 36% partial response rate in a
group of 26 patients with metastatic or unresec-
table GBC.
8 In a Phase II trial of 1,200 mg/m
2 of
gemcitabine given weekly for three weeks fol-
lowed by a two-week rest period, 3 of 19 patients
with biliary tract cancer or GBC (16%) achieved a
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partial response.
9 The median survival period was
6.5 months and the time to disease progression
was 2.5 months. A Phase II trial of gemcitabine
given every other week at a dose of 2,200 mg/m
2
reported a response rate of 22% and a median
survival period of 11.5 months.
10 The combina-
tion of gemcitabine, 5-FU, and leucovorin (LV) has
been evaluated in several Phase I trials, building
on preclinical studies demonstrating synergistic
and additive effects in an ex vivo tumor model.
11
Three Phase I studies evaluating the combination
of gemcitabine, 5-FU, and LV have been com-
pleted to date.
12,13 All these studies showed evi-
dence of meaningful antitumor activity and few
significant side effects. Capecitabine (Xeloda ;
Hoffman La Roche, Basel, Switzerland) is a selec-
tive, oral fluoropyrimidine carbamate that gener-
ates 5-FU selectively in tumor tissues. This selec-
tivity is achieved by the enzyme thymidine phos-
phorylase, which is responsible for the final
conversion of capecitabine to 5-FU and is found
at much higher levels in cancers compared with
normal tissues.
14-16 Capecitabine offers the pos-
sibility of continuous tumor exposure to 5-FU by
preferential activation at the tumor site, while
potentially minimizing the exposure of healthy
body tissues to systemic 5- FU.
17,18 We performed
this study to further investigate the potential of
CapGem in previously untreated patients with
advanced and/or metastatic GBC.
MATERIALS AND METHODS
Eligibility
Patients with histologically confirmed unresec-
table or metastatic GBC, who were at least 18
years of age and who had a Karnofsky Perform-
ance Status of > 70% were included. The fol-
lowing hematologic and chemistry parameters
were recommended: neutrophils > 1.5 × 10
9/L,
platelet count > 100 × 10
9/L, total bilirubin level <
three times the upper limit of normal, aspartate
aminotransferase (AST) level < five times the
upper limit of normal, and creatinine level < one
and a half times the upper limit of normal.
Previous use of capecitabine or gemcitabine, and
previous receipt of radiation therapy to more than
25% of the bone marrow were the exclusion cri-
teria. Pregnant or lactating patients were excluded
from the study. Female participants were required
to use adequate contraceptive methods to prevent
pregnancy during treatment. Other contraindica-
tions included a history of brain or other central
nervous system metastases. Previous biologic or
immunologic therapy was not allowed within four
weeks of study entry. Any history of a previous
malignancy diagnosed within five years was not
allowed, with the exception of basal or squamous
cell carcinoma or skin and cervical carcinoma in
situ.
Treatment and dose modification
Capecitabine (1,000 mg/m
2) was administered
orally twice a day for 14 consecutive days fol-
lowed by one week of rest. Gemcitabine was
given as a 30 min IV infusion on Days 1 and 8
of each cycle at a dose of 1,000 mg/m
2. Cycles
were repeated every 21 days provided that
patients had recovered sufficiently from the drug-
related side effects. Prophylactic administration of
recombinant human granulocyte colony-stimu-
lating factor (rhG-CSF) was not allowed. In cases
where the patient had Grade 3 or 4 afebrile neu-
tropenia, subsequent cycles were repeated with
rhG-CSF prophylactic administration. If the
patient had febrile neutropenia or Grade 3 or 4
neutropenia despite the prophylactic administra-
tion of rhG-CSF, capecitabine and gemcitabine
doses were reduced by 25%. In cases of Grade 3
or 4 thrombocytopenia lasting for more than 5
days, the doses of both drugs were also reduced
by 25%. The dose of capecitabine was reduced by
25% in cases of Grade 3 or 4 diarrhea or hand-foot
syndrome.
Efficacy and safety evaluation
Tumor assessments according to RECIST crite-
ria were performed at six-week intervals by the
investigators. Tumor lesions were assessed by
computed tomography (CT) scanning, X-rays or
magnetic resonance imaging (MRI); objective tu-
mor response was based on the dimensions of
measurable marker lesions, measured by the same
radiologist throughout the study. Time to progres-Jae-Yong Cho, et al.
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sion (TTP) was calculated as the time from the
first treatment to the time the patient was first
recorded as having progressive disease (PD), or
the date of death if the patient died before PD was
demonstrated. Survival was monitored every
three months after the patient completed treat-
ment. Safety was monitored throughout the study
and for 28 days after the last study treatment.
Adverse events were graded according to the Na-
tional Cancer Institute-Common Toxicity Criteria
(NCI-CTC). Hand-foot syndrome was graded as
in previous capecitabine studies.
19 TTP and sur-
vival were analyzed by the Kaplan-Meier product
limit method. Those who did not receive at least
one dose of study medication or for whom no
follow-up safety information was available were
excluded from the safety analysis.
RESULTS
Patient characteristics
Twenty-four patients (18 women and 6 men)
were enrolled between June 2001 and December
2004. Patients who received at least one dose of
CapGem were considered evaluable for efficacy
and safety. As shown in Table 1, the majority of
patients (75%) had Stage IV disease and the most
commonly affected metastatic sites were the liver
(67%) and the lymph nodes (54%). Fourteen
patients had undergone one or more type of sur-
gery.
Treatment administration
A median of four courses of treatment (range,
1-16 courses) were given. Reasons for discon-
tinuing study treatment included disease progres-
sion (79%), toxicity (10%), or other reasons (11%).
During Cycle 1, 96.7% (range, 86-100%) and 98.7%
(range, 87-100%) of the planned dose of capecita-
bine and gemcitabine, respectively, were given.
During Cycle 2, 95.1% (range, 83-100%) and 96.3%
(range, 85-100%) of the planned doses of capeci-
tabine and gemcitabine, respectively, were given.
Despite the need for dose modifications, 90% of
patients received all three weeks of treatment with
both drugs during the first two cycles of therapy.
Efficacy
Eight of the 24 patients (33%, 95% CI, 19-48%)
had a partial response (PR) and ten patients (42%)
had stable disease (SD) (investigator-determined
responses, Table 2). The median TTP was 6.0
months (95% CI, 3.0-8.1 months), and the median
overall survival was 16 months (95% CI, 13.8-18.3
months). The 1-year actuarial survival rate was
58% (Fig. 1). Efficacy data are shown in Table 2.
Table 1. Patient Characteristics
Variables No. (%)
Total No. of patients treated 24
Age (yrs)
Median
Range
62
41 - 78
Sex
Male
Female
6 (25)
18 (75)
Karnofsky performance status (%)
Median
Range
90
70 - 100
Disease stage
Locally advanced
Metastatic
12 (50)
18 (75)
Metastatic sites
Liver
Lymph nodes
Peritoneal seeding
Lung
Bone
16 (67)
13 (54)
6 (25)
4 (17)
2 (8)
Patients with 1 surgical intervention 14 (60)
Table 2. Efficacy Data
Evaluable factors No. (%) 95% CI (%)
Response (investigators)
Complete response (CR) 0 (0)
Partial response (PR) 8 (33) 19 - 48
Stable disease (SD) 10 (42)
Progressive disease (PD) 6 (25)
Response rate (CR + PR) 8 (33) 19 - 48
Median TTP (months) 6 3.8 - 8.1
Median OS (months) 16 13.8 - 18.3
*RECIST criteria.
TTP, time to progression; OS, overall survival.A Phase II Study of CapGem in Advanced GBC
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Safety
Table 3 summarizes the toxicity observations.
Non-hematological adverse events (Grade 2 per-
centage/Grade 3 percentage) were: nausea (25%/
8%), hand-foot syndrome (17%/8%), general
weakness (17%/8%), anorexia (17%/4%), stoma-
titis (13%/4%), vomiting (13%/4%), constipation
(4%/4%), and diarrhea (4%/4%). Grade 3 neutr-
openia, anemia, and thrombocytopenia occurred
in 13%, 8% and 8% of patients, respectively. Two
patients developed febrile episodes. Grade 2 and
Grade 3 hepatotoxicity developed in 8% and 8%
of patients, respectively. No Grade 4 toxicity was
seen. No patient discontinued treatment because
of abnormal laboratory values. No deaths attri-
buted to toxicity occurred during the study. There
were 13 deaths reported during the study, the
majority of which occurred more than 28 days
after the end of the planned treatment schedule.
All of the deaths were related to disease progres-
sion.
DISCUSSION
A modest response was observed in the current
Phase II study of CapGem combination chemo-
therapy for patients with locally advanced or
metastatic GBC. The drug combination was gene-
rally well-tolerated. Overall, there were eight
confirmed partial responses (PR) observed, with
an estimated PR rate of 33% (95% CI, 19-48%).
This compares with published PR rates of 16-30%
reported for the use of gemcitabine alone.
8,19 The
median survival in our trial was 16 months, which
is better than the 6.5-11.5 months in the single-
Fig. I. The median TTP was 6.0 months (95% CI, 3.0-8.1
months), and the median overall survival was 16 months
(95% CI, 13.8-18.3 months). The 1-year actuarial survival
rate was 58%.
Table 3. Toxicities of Chemotherapy (N=24)
Toxicity (NCI-CTC) Grade 1-2 (%) Grade 3 (%) Grade 4
Hematologic
Neutropenia
Anemia
Thrombocytopenia
Nonhematologic
Nausea
HFS*
General weakness
Anorexia
Stomatitis
Vomiting
Constipation
Diarrhea
Hepatic
AST/ALT elevation
Bilirubin elevation
4 (17)
4 (17)
3 (13)
6 (25)
4 (17)
4 (17)
4 (17)
3 (13)
3 (13)
1 (4)
1 (4)
1 (4)
1 (4)
3 (13)
2 (8)
2 (8)
2 (8)
2 (8)
2 (8)
1 (4)
1 (4)
1 (4)
1 (4)
1 (4)
1 (4)
1 (4)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
*HFS, hand-foot syndrome.Jae-Yong Cho, et al.
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agent gemcitabine trials. The combination of
capecitabine and gemcitabine, based on the dose
and schedule as used in our trial, has better
activity than gemcitabine alone. It is possible that
capecitabine may enhance the activity of the com-
bination. In a recent single-arm study of oral
capecitabine therapy, a 50% treatment response
was reported in patients with GBC.
20 Further, in
an interim report of a trial using capecitabine and
gemcitabine, five of 15 patients with biliary tract
cancers achieved a PR.
21 These results suggest that
capecitabine and gemcitabine may be a reasonable
treatment combination for biliary tract cancers, in-
cluding GBC. In human tumor xenograft models,
oral administration of capecitabine yielded sub-
stantially higher concentrations of 5-FU in tumor
specimens than in specimens of plasma or normal
tissue. It is noteworthy that levels of 5-FU after
administration of capecitabine were much higher
than those achieved by IV administration of 5-FU
at doses producing equal levels of toxicity. The
susceptibility of the xenografts to capecitabine
was correlated with levels of the enzyme thymi-
dine phosphorylase in tumor tissue specimens.
Therefore, the efficacy of capecitabine may be
optimized by selecting candidates for treatment
on the basis of thymidine phosphorylase expres-
sion or by combining this agent with other agents
that can upregulate thymidine phosphorylase ex-
pression within tumor tissue.
15,16
Phase II trials of approximately 130 patients
treated with a chemotherapy regimen of gemcita-
bine in combination with other agents show
response rates ranging from 9 to 53%, with a
tolerable toxicity profile.
22-27 Overall survival in
these studies ranged from 6.3 to 16 months. Most
of these studies have included all biliary tract
cancers. A recent Phase II study using the com-
bination of gemcitabine and cisplatin in advanced
GBC has reported high activity (64% response
rate) with a tolerable toxicity profile.
28 The present
data and literature review, however, do not
address the question whether this combination is
superior or equivalent to single-agent gemcitabine
or CapGem combination. Thus, further confirma-
tive Phase III trials will be needed.
Nausea and hand-foot syndrome were the most
common side effects of treatment, and hema-
tologic toxicity was limited to Grades 2 and 3. The
mildness of the observed toxicity may be attribu-
table to the less aggressive starting dose of cape-
citabine (1,000 mg/m
2) used for this group of
patients. The use of 1,000 mg/m
2 capecitabine has
become common in the treatment of patients with
other malignancies, such as colorectal carcinoma;
this reduced dose was suggested by Borner et
al.,
29 who also recommended the use of 1,000 mg/
m
2 twice daily when capecitabine is used in com-
bination with oxaliplatin. Although impaired
hepatic function can exacerbate toxicity or inhibit
the efficacy of many agents, the presence of mild-
to-moderate hepatic dysfunction had no clinically
significant effect on the pharmacokinetics of
capecitabine and its metabolites.
17 This finding
suggests that the CapGem regimen may be useful
for patients with hepatobiliary carcinoma, in-
cluding patients with mildly-to-moderately im-
paired hepatic function.
Further research in this area should be directed
at finding the best cytotoxic agent for combination
with capecitabine or gemcitabine, or altering the
dose intensity or route of administration in ad-
vanced gallbladder cancer. A larger trial of gem-
citabine combined with cisplatin compared with
CapGem needs to be conducted. Also, the role of
the CapGem combination as an adjuvant treat-
ment for suboptimally resected patients should be
further pursued.
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